NewAmsterdam Pharma presented full data from the prespecified Alzheimer’s disease (AD) biomarker analysis in the Phase 3 BROADWAY clinical trial at the 2025 Alzheimer’s Association International Conference (AAIC). The data confirmed that obicetrapib 10 mg daily for 12 months resulted in statistically significant lower absolute changes in plasma p-tau217, a key AD pathology biomarker.
The reduction in p-tau217 was observed in both the full analysis set (p=0.0019; n=1,515) and in ApoE4 carriers (p=0.0215; n=367). Notably, in APOE4/E4 carriers, the highest risk category for AD, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo (p=0.010).
Favorable trends were also observed across additional AD biomarkers, including neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP), with the greatest effect generally seen in carriers of two E4 proteins. These results build on obicetrapib’s cardiometabolic profile and highlight its potential to address converging pathways of cardiovascular and neurovascular disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.